3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
12
Neuroblastoma
8
Wilms Tumor
7
Osteosarcoma
7
Medulloblastoma
7
Lymphoma, Non-Hodgkin
7
Hepatoblastoma
7
Rhabdoid Tumor
6
Neuroectodermal Tumors, Primitive, Peripheral
6
Histiocytosis, Langerhans-Cell
6
Ependymoma
6
Central Nervous System Neoplasms
6
Sarcoma
5
Rhabdomyosarcoma
5
Brain Neoplasms
5
Sarcoma, Ewing
4
Urinary Bladder Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Interventions
Temozolomide
23
Bevacizumab
18
Cyclophosphamide
9
Carboplatin
7
Lomustine
6
Irinotecan
6
3-Iodobenzylguanidine
6
Topotecan
5
Radiotherapy
5
Filgrastim
5
Radiosurgery
4
Nivolumab
4
Everolimus
4
Etoposide
4
Busulfan
4
sonidegib
3
pembrolizumab
3
olaparib
3
fludarabine phosphate
3
fludarabine
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Vincristine
3
Thiotepa
3
Sirolimus
3
Melphalan
3
IL13-PE38
3
Drug Therapy
3
Antilymphocyte Serum
3
verubulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
X-Rays
×
CNS
×
Clear all
NCT02636634
2016-04-11
CV-METANEC
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
90 enrolled